3-Amino-pyrazolo[3,4-d]pyrimidines as p38α kinase inhibitors: Design and development to a highly selective lead

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 11, 2011, Pages 3452-3456

  Soth, Michael ^a   Abbot, Sarah ^a   Abubakari, Allassan ^a   Arora, Nidhi ^a   Arzeno, Humberto ^a   Billedeau, Roland ^a   Dewdney, Nolan ^a   Durkin, Kieran ^a   Frauchiger, Sandra ^a   Ghate, Manjiri ^a   Goldstein, David M ^a   Hill, Ronald J ^a   Kuglstatter, Andreas ^a   Li, Fujun ^a   Loe, Brad ^a   McCaleb, Kristen ^a   McIntosh, Joel ^a   Papp, Eva ^a   Park, Jaehyeon ^a   Stahl, Martin ^b   Sung, Man Ling ^a   Suttman, Rebecca ^a   Swinney, David C ^a   Weller, Paul ^a   Wong, Brian ^a   Zecic, Hasim ^a   Gabriel, Tobias ^a   more..

^a ROCHE BIOSCIENCE   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Kinase; Kinase inhibitor; p38

Indexed keywords

3 AMINO PYRAZOLO[3,4 D]PYRIMIDINE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; DRUG DESIGN; DRUG DEVELOPMENT; DRUG STRUCTURE; DRUG SYNTHESIS;

ANIMALS; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; ENZYME ACTIVATION; ENZYME INHIBITORS; INHIBITORY CONCENTRATION 50; MITOGEN-ACTIVATED PROTEIN KINASE 14; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PYRAZOLES; PYRIMIDINES; RATS;

EID: 79956123752     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.03.098     Document Type: Article

References (25)

1. G. Schett, J. Zwerina, and G. Firestein Ann. Rheum. Dis. 67 2008 909
2. D.M. Goldstein, and T. Gabriel Curr. Top. Med. Chem. 5 2005 1017
3. J. Westra, and P.C. Limburg Mini-Rev. Med. Chem. 6 2006 867
4. D.M. Goldstein, A. Kuglstatter, Y. Lou, and M.J. Soth J. Med. Chem. 53 2010 2345
5. Genovese, M. C.; Gao, L.; Yin, J.; Smith, S.; Weinblatt, M.; Smolen, J.; Wang, X.; Schieven, G.; Garcia-Meijide, J. A.; Latek, R.; Pasternak, R.; Kaul, S.; Roy, A.; Raymond, R., Thienel, U.; Wang, J. Presented at the American College of Rheumatology Scientific Meeting; Atlanta, GA, 2010; Poster 1119.
6. G. Schett, C. Stach, J. Zwerina, R. Voll, and B. Manger Arthritis Rheum. 58 2008 2936
7. M.C. Genovese Arthritis Rheum. 602 2009 317
8. D. Hammaker, and G.S. Firestein Ann. Rheum. Dis. 69 2010 77 (Suppl. I
9. R.J. Hill, K. Dabbagh, D. Phippard, C. Li, R.T. Suttmann, M. Welch, E. Papp, K.W. Song, K.-C. Chang, D. Leaffer, Y.-N. Kim, R.T. Roberts, T.S. Zabka, D. Aud, J. Dal Porto, A.M. Manning, S.L. Peng, D.M. Goldstein, and B.R. Wong J. Pharmacol. Exp. Ther. 327 2008 610
10. S.B. Cohen, T.T. Cheng, V. Chindalore, N. Damjanov, R. Burgos-Vargas, P. Delora, K. Zimany, H. Travers, and J.P. Caulfield Arthritis Rheum. 60 2009 335
11. R.E. Alten, C. Zerbini, S. Jeka, F. Irazoque, F. Khatib, P. Emery, A. Bertasso, M. Rabbia, and J.P. Caulfield Ann. Rheum. Dis. 69 2010 364
12. D.M. Goldstein, M.J. Soth, T. Gabriel, N. Dewdney, A. Kuglstatter, H. Arzeno, J. Chen, W. Bingenheimer, S.A. Dalrymple, J. Dunn, R. Farrell, S. Frauchiger, J. La Fargue, M. Ghate, B. Graves, R.J. Hill, F. Li, R. Litman, B. Loe, J. McIntosh, D. McWeeney, E. Papp, J. Park, H.F. Reese, R.T. Roberts, D. Rotstein, B. San Pablo, K. Sarma, M. Stahl, M. Sung, R.T. Suttman, E.B. Sjogren, Y. Tan, A. Trejo, M. Welch, P. Weller, B.R. Wong, and H. Zecic J. Med. Chem. 54 2011 2255
13. W. Huber, and F. Mueller Curr. Pharm. Des. 12 2006 3999
14. Representative experimental procedures for compounds can be found in WO 2007/023110.
15. M.A. Fabian, W.H. Biggs III, D.K. Treiber, C.E. Atteridge, M.D. Azimioara, M.G. Benedetti, T.A. Carter, P. Ciceri, P.T. Edeen, M. Floyd, J.M. Ford, M. Galvin, J.L. Gerlach, R.M. Grotzfeld, S. Herrgard, D.E. Insko, M.A. Insko, A.G. Lai, J.-M. Lelias, S.A. Mehta, Z.V. Milanov, A.M. Velasco, L.M. Wodicka, H.K. Patel, P.P. Zarrinkar, and D.J. Lockhart Nat. Biotechnol. 23 2005 329
16. 8 compound 23 at 10 μM displaces ligands for the following kinases at the percents indicated: p38α, p38β, JNK1, JNK2, and JNK3 (100%); CSNK1E (88%); GAK (87%); and STK36 (74%). Ambit Kd's were determined for p38α (1.2 nM), p38β (8.7 nM), JNK1 (110 nM), JNK2 (16 nM) and JNK3 (16 nM).
17. B. Herberich, G-Q. Cao, P.P. Chakrabarti, J.R. Falsey, L. Pettus, R.M. Rzasa, A.B. Reed, A. Reichelt, K. Sham, M. Thaman, R.P. Wurz, S. Xu, D. Zhang, F. Hsieh, M.R. Lee, R. Syed, V. Li, D. Grosfeld, M.H. Plant, B. Henkle, L. Sherman, S. Middleton, L.M. Wong, and A.S. Tasker J. Med. Chem. 51 2008 6271
18. 3S) C, H, N. Specific rotation (MeOH)-34.000 °/g/100 mL.
19. All animal procedures were approved by the Institutional Animal Care and Use Committee of Roche Palo Alto. Compound was administered (p.o.) to Hanover-Wistar rats 0.5 h prior to challenge with 50 μg/kg LPS (i.e., 0.9% saline). Serum was collected 1.5 h after LPS injection and analyzed for TNF-α levels (ELISA) and drug concentrations.
20. M. Rarey, B. Kramer, T. Lengauer, and G. Klebe J. Mol. Biol. 261 1996 470
21. M. Rarey, B. Kramer, and T. Lengauer J. Comput. Aided Mol. Des. 11 1997 369
22. P.R. Gerber, and K. Muller J. Comput. Aided Mol. Des. 9 1995 251
23. P.R. Gerber J. Comput. Aided Mol. Des. 12 1998 37
24. W.L. DeLano The PyMOL Molecular Graphics System 2002 DeLano Scientific Palo Alto, CA, USA http://www.pymol.org
25. A. Trejo, Humberto Arzeno, Michelle F. Browner, Sushmita Chanda, Soan Cheng, Daniel D. Comer, Stacie A. Dalrymple, Pete Dunten, JoAnn La Fargue, Brett Lovejoy, Jose Freire-Moar, Julie Lim, Joel McIntosh, Jennifer Miller, Eva Papp, Deborah Reuter, Rick Roberts, Florentino Sanpablo, John Saunders, Kyung Song, Armando Villasenor, Stephen D. Warren, Mary Welch, Paul Weller, Phyllis E. Whiteley, Lu Zeng, and David M. Goldstein J. Med. Chem. 46 2003 4702